Presentations

    Do We Need “Big” Or Rather Consecutive Studies In Epidemiology?

    Kallischnigg, G.; Kaelin, E.; H-Urban, H-J. Urban.; Weitkunat, R.

    Conference date
    Jun 19, 2007
    Conference name
    Society for Epidemiologic Research (SER) 2007
    Link to more information
    Topic
    Summary

    Many investigators have suggested that very large studies are needed in epidemiology. Large studies, which are often organized as multi-center or even multi-national studies, are indeed essential if effects are small, as they often are in molecular and genetic epidemiological research. As with diagnostic tests, however, the proportion of true positive findings obtained in such studies depends to a large degree on the prior probability of the effect as well as on the sensitivity and specificity of the measurement. In statistical terms, the latter two correspond to power and type I error, respectively. In analogy to the calculation of the positive predictive value (PPV), a parameter often used to assess the results of a given study, the true positive report probability (TPR) can be calculated. The TPR is the probability of the alternative hypothesis being true, given that a significant finding has been obtained. It can be shown that the TPR does not increase substantially by increasing the sample size beyond 1000 individuals, if the prior probability of the true alternative hypothesis is low. However, as in diagnostic tests, the TPR will increase dramatically if the finding is replicated. From this it follows that, independent of sample size considerations, it is necessary to conceive research strategies which pre-plan for replications in order to avoid false positive results. 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.